PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma
Clinical trial NCT05466474 · UNKNOWN
Trial details
- NCT number
- NCT05466474
- Sponsor
- Henan Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-30
- Primary completion
- 2024-04-30
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.